FDA approves treatments for heart failure caused by rare disease
(HealthDay)—Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules have been approved to treat adults with cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM), the U.S. Food and Drug Administration announced today. Recommended dosage is four 20-mg capsules of Vyndaqel once daily or a single 61-mg capsule of Vyndamax once daily, according to the manufacturer. The two drugs, which are the first approved […]
Continue reading »